All In Biotech

Drug Trial Radar · NCT07542483

A Study of Lebrikizumab in Adults With Nummular Eczema

A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Study With a Double-Blind Extension Evaluating Efficacy and Safety of Lebrikizumab Administered to Adult Patients With Nummular Eczema Who Are Not Adequately Controlled With Topical Corticosteroids or When This Treatment is Not Medically Advisable (LUMINE)

Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 270 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

270

Planned (sponsor's estimate)

Start

Apr 24, 2026

Primary completion

Aug 2028

Study completion Feb 2029

Sponsor

Lead sponsor
Almirall, S.A.Industry
Sponsor type
Industry
First posted
Apr 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of the study is to evaluate the efficacy, safety, and tolerability of lebrikizumab treatment in adult participants with Nummular Eczema (NE) who are not adequately controlled with Topical corticosteroids (TCS) or when this treatment is not medically advisable.

Conditions

  • Nummular Eczema

Interventions

  • LebrikizumabDrug

    Lebrikizumab SC injection.

  • PlaceboOther

    Matching placebo SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Investigator Global Assessment (IGA) Score of 0 or 1 and a >=2-point Reduction from Baseline at Week 24Time frame: Baseline, Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Alm Site 1

    Freiburg im Breisgau, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.